

297mm

210mm

pharmaniaga®



Covinace

Perindopril Tert-butylamine 8mg



Tablet 8 mg

DESCRIPTION

White to off white, round, biconvex tablet with intersected breakline on one side and plain on the other.

COMPOSITION

Each tablet contains Perindopril tert-butylamine 8mg

PHARMACODYNAMICS

Perindopril is a converting enzyme inhibitor (CEI) of angiotensin I into angiotensin II. The converting enzyme, or kinase, is an exopeptidase that allows conversion of angiotensin I into the vasoconstrictor angiotensin II as well as causing the degradation of the vasodilator bradykinin into an inactive heptapeptide. Inhibition of ACE results in a reduction of angiotensin II in the plasma, which leads to increased plasma renin activity (by inhibition of the negative feedback of renin release) and reduced secretion of aldosterone. Since ACE inactivates bradykinin, inhibition of ACE also results in an increased activity of circulating and local kallikrein-kinin systems (and thus also activation of the prostaglandin system). It is possible that this mechanism contributes to the blood pressure-lowering action of ACE inhibitors and is partially responsible for certain of their side effects (e.g. cough).

Perindopril acts through its active metabolite perindoprilat and the other metabolites are inactive.

Hypertension

The usual effective dose in mild to moderate hypertension is 4 mg per day given in a single dose. Efficacy is maintained throughout the 24-hour cycle and the peak antihypertensive effect is reached 4 to 6 hours after a single dose of perindopril.

Fall in blood pressure is rapidly obtained and, in responding patients, normal values are reached within 1 month and are maintained without therapeutic escape.

There is no rebound effect on withdrawal of treatment.

In man, perindopril has vasodilator properties, it restores the elastic qualities of the large arteries and reduces left ventricular hypertrophy.

Combination with a diuretic potentiates the antihypertensive effect.

PHARMACOKINETICS

After oral administration, the absorption of perindopril is rapid and the peak concentration complete within 1 hour. The plasma half-life of perindopril is equal to 1 hour. Perindopril is a prodrug, 27% of the administered perindopril dose reaches the bloodstream as the active metabolite perindoprilat. In addition to active perindoprilat, perindopril yields 5 metabolites, all inactive. The peak plasma concentration of perindoprilat is achieved within 3 to 4 hours. Perindopril should be administered orally in a single daily dose in the morning before a meal since ingestion of food decreases conversion to perindoprilat. It has been demonstrated a linear relationship between the dose of perindopril and its plasma exposure. The volume of distribution is approximately 0.2 l/kg for unbound perindoprilat. Protein binding of perindoprilat to plasma proteins is 20%, principally to angiotensin converting enzyme, but is concentration-dependent. Perindopril is eliminated in the urine and the terminal half-life of the unbound fraction is approximately 17 hours, resulting in steady-state within 4 days.

Special population:

Elimination of perindoprilat is decreased in the elderly, and also in patients with heart or renal failure. Dosage adjustment in renal insufficiency is desirable

depending on the degree of impairment (creatinine clearance). Dialysis clearance of perindoprilat is equal to 70 ml/min, Perindopril kinetics are modified in patients with cirrhosis. Hepatic clearance of the parent molecule is reduced by half. However, the quantity of perindoprilat formed is not reduced and therefore no dosage adjustment is required.

INDICATIONS

Hypertension:

Treatment of hypertension.

Stable coronary artery disease:

Reduction of risk of cardiac events in patients with a history of myocardial infarction and/or revascularisation.

CONTRAINDICATIONS

- Hypersensitivity to perindopril, to any of the excipients listed or to any other ACE inhibitor,
- History of angioedema associated with previous ACE inhibitor therapy,
- Hereditary or idiopathic angioedema,
- Second and third trimesters of pregnancy,
- Concomitant use of Covinace Tablet with products containing aliskiren in patients with diabetes mellitus or renal impairment GFR [glomerular filtration rate] < 60 ml/min/1.73 m²)

WARNINGS AND PRECAUTIONS

INCREASED RISK OF BIRTH DEFECTS, FOETAL AND NEONATAL MORBIDITY AND DEATH WHEN USED THROUGHOUT PREGNANCY.

ACE inhibitors can cause foetal and neonatal morbidity and death when administered to pregnant women. When pregnancy is detected, ACE inhibitors should be discontinued as soon as possible.

The use of ACE inhibitors during the second and third trimesters of pregnancy has been associated with foetal and neonatal injury, including hypotension, neonatal skull hypoplasia, anuria, reversible or irreversible renal failure and death.

Oligohydramnios has also been reported, presumably resulting from decreased foetal renal function; oligohydramnios in this setting has been associated with foetal limb contractures, craniofacial deformation and hypoplastic lung development.

Prematurity, intrauterine growth retardation, patent ductus arteriosus, and other structural cardiac malformations, as well as neurologic malformations, have been reported following exposure to ACE inhibitors during the first trimester of pregnancy.

When patients become pregnant, healthcare providers should make every effort to discontinue the use of perindopril as soon as possible. Rarely (probably less often than once in every thousand pregnancies), no alternative to ACE inhibitors will be found. In these rare cases, the pregnant patients should be apprised of the potential hazards to their foetuses, and serial ultrasound examinations should be performed to assess the intra-anniotic environment.

If oligohydramnios is observed, perindopril should be discontinued unless it is considered life-saving for the pregnant patients. Contraction stress testing (CST), a non-stress test (NST) or biophysical profiling (BPP) may be appropriate, depending upon the week of pregnancy. Patients and healthcare providers should be aware, however, that oligohydramnios may not appear until after the foetus has sustained irreversible injury.

Infants with histories of in utero exposure to ACE inhibitors should be closely observed for hypotension, oliguria and hyperkalaemia. If oliguria occurs, attention should be directed toward support of blood pressure and renal perfusion. Exchange transfusion or dialysis may be required as a means of reversing hypotension and/or substituting for disordered renal function. Perindopril, which crosses the placenta, can theoretically be removed from the neonatal circulation by these means, but limited experience has not shown that such removal is central to the treatment of these infants.

Stable coronary artery disease:

If an episode of unstable angina pectoris (major or not) occurs during the first month of perindopril treatment, a careful appraisal of the benefit/risk should be performed before treatment continuation.

Hypotension:

ACE inhibitors may cause a fall in blood pressure. Symptomatic hypotension is seen rarely in uncomplicated hypertensive patients and is more likely to occur in patients who have been volume-depleted (e.g. by diuretic therapy, dietary salt restriction, dialysis, diarrhoea or vomiting, or who have severe renin-dependent hypertension). In patients with symptomatic heart failure, with or without associated renal insufficiency, symptomatic hypotension has been observed. This is most likely to occur in those patients with more severe degrees of heart failure, as reflected by the use of high doses of loop diuretics, hyponatraemia or functional renal impairment.

In patients at increased risk of symptomatic hypotension, initiation of therapy and dose adjustment should be closely monitored. Similar considerations apply to patients with ischaemic heart or cerebrovascular disease in whom an excessive fall in blood pressure could result in a myocardial infarction or cerebrovascular accident.

If hypotension occurs, the patient should be placed in the supine position and, if necessary, should receive an intravenous infusion of sodium chloride 9 mg/ml (0.9%) solution. A transient hypotensive response is not a contraindication to further doses, which can be given usually without difficulty once the blood pressure has increased after volume expansion.

In some patients with congestive heart failure who have normal or low blood pressure, additional lowering of systemic blood pressure may occur with Covinace

Tablet. This effect is anticipated and is usually not a reason to discontinue treatment. If hypotension becomes symptomatic, a reduction of dose or discontinuation of Covinace Tablet may be necessary.

Aortic and mitral valve stenosis/ hypertrophic cardiomyopathy:

As with other ACE inhibitors, Covinace Tablet should be given with caution to patients with mitral valve stenosis and obstruction in the outflow of the left ventricle such as aortic stenosis or hypertrophic cardiomyopathy.

Renal impairment:

In cases of renal impairment (creatinine clearance < 60ml/min) the initial perindopril dosage should be adjusted according to the patient's creatinine clearance and then as a function of the patient's response to treatment. Routine monitoring of potassium and creatinine are part of normal medical practice for these patients.

In patients with symptomatic heart failure, hypotension following the initiation of therapy with ACE inhibitors may lead to some further impairment in renal function. Acute renal failure, usually reversible, has been reported in this situation.

In some patients with bilateral renal artery stenosis or stenosis of the artery to a solitary kidney, who have been treated with ACE inhibitors, increases in blood urea and serum creatinine, usually reversible upon discontinuation of therapy, have been seen. This is especially likely in patients with renal insufficiency. If renovascular hypertension is also present there is an increased risk of severe hypotension and renal insufficiency. In these patients, treatment should be started under close medical supervision with low doses and careful dose titration. Since treatment with diuretics may be a contributory factor to the above, they should be discontinued and renal function should be monitored during the first weeks of Covinace Tablet therapy.

Some hypertensive patients with no apparent pre-existing renal vascular disease have developed increases in blood urea and serum creatinine, usually minor and transient, especially when Covinace Tablet has been given concomitantly with a diuretic. This is more likely to occur in patients with pre-existing renal impairment. Dosage reduction and/or discontinuation of the diuretic and/or Covinace Tablet may be required.

Haemodialysis patients:

Anaphylactoid reactions have been reported in patients dialysed with high flux membranes, and treated concomitantly with an ACE inhibitor. In these patients, consideration should be given to using a different type of dialysis membrane or different class of antihypertensive agent.

Kidney transplantation:

There is no experience regarding the administration of Covinace Tablet in patients with a recent kidney transplantation.

Hypersensitivity/Angioedema:

Angioedema of the face, extremities, lips, mucous membranes, tongue, glottis and/or larynx has been reported rarely in patients treated with ACE inhibitors, including Covinace Tablet. This may occur at any time during therapy. In such cases, Covinace Tablet should promptly be discontinued and appropriate monitoring should be initiated and continued until complete resolution of symptoms has occurred. In those instances where swelling was confined to the face and lips the condition generally resolved without treatment, although antihistamines have been useful in relieving symptoms.

Angioedema associated with laryngeal oedema may be fatal. Where there is involvement of the tongue, glottis or larynx, likely to cause airway obstruction, emergency therapy should be administered promptly. This may include the administration of adrenaline and/or the maintenance of a patent airway. The patient should be under close medical supervision until complete and sustained resolution of symptoms has occurred.

Patients with a history of angioedema unrelated to ACE inhibitor therapy may be at increased risk of angioedema while receiving an ACE inhibitor.

Intestinal angioedema has been reported rarely in patients treated with ACE inhibitors. These patients presented with abdominal pain (with or without nausea or vomiting); in some cases, there was no prior facial angioedema and C-1 esterase levels were normal. The angioedema was diagnosed by procedures including abdominal CT scan, or ultrasound or at surgery and symptoms resolved after stopping the ACE inhibitor. Intestinal angioedema should be included in the differential diagnosis of patients on ACE inhibitors presenting with abdominal pain.

The combination of perindopril with sacubitril/valsartan is contraindicated due to the increased risk of angioedema. Sacubitril/valsartan must not be initiated until 36 hours after taking the last dose of perindopril therapy. If treatment with sacubitril/valsartan is stopped, perindopril therapy must not be initiated until 36 hours after the last dose of sacubitril/valsartan. Concomitant use of other NEP inhibitors (e.g. rabeceadotril) and ACE inhibitors may also increase the risk of angioedema. Hence, a careful benefit-risk assessment is needed before initiating treatment with NEP inhibitors (e.g. rabeceadotril) in patients on perindopril.

Concomitant use of mTOR inhibitors (e.g. sirolimus, everolimus, temsirolimus) Patients taking concomitant mTOR inhibitors (e.g. sirolimus, everolimus, temsirolimus) therapy may be at increased risk for angioedema (e.g. swelling of the airways or tongue, with or without respiratory impairment)

Anaphylactoid reactions during low-density lipoproteins (LDL) apheresis: Rarely, patients receiving ACE inhibitors during low-density lipoprotein (LDL) apheresis with dextran sulphate have experienced life-threatening anaphylactoid reactions. These reactions were avoided by temporarily withholding ACE inhibitor therapy prior to each apheresis.

Anaphylactoid reactions during desensitization:

Patients receiving ACE inhibitors during desensitisation treatment (e.g. hymenoptera venom) have experienced anaphylactoid reactions. In the same patients, these reactions have been avoided when the ACE inhibitors were temporarily withheld, but they reappeared upon inadvertent rechallenge.

Hepatic failure:

Rarely, ACE inhibitors have been associated with a syndrome that starts with cholestatic jaundice and progresses to fulminant hepatic necrosis and (sometimes) death. The mechanism of this syndrome is not understood. Patients receiving ACE inhibitors who develop jaundice or marked elevations of hepatic enzymes should discontinue the ACE inhibitor and receive appropriate medical follow-up.

Neutropenia/Agranulocytosis/ Thrombocytopenia/ Anaemia:

Neutropenia/agranulocytosis, thrombocytopenia and anaemia have been reported in patients receiving ACE inhibitors. In patients with normal renal function and no other complicating factors, neutropenia occurs rarely. Perindopril should be used with extreme caution in patients with collagen vascular disease, immunosuppressant therapy, treatment with allopurinol or procainamide, or a combination of these complicating factors, especially if there is pre-existing impaired renal function.

Some of these patients developed serious infections, which in a few instances did not respond to intensive antibiotic therapy. If perindopril is used in such patients, periodic monitoring of white blood cell counts is advised and patients should be instructed to report any sign of infection (e.g. sore throat, fever).

Race:

ACE inhibitors cause a higher rate of angioedema in black patients than in non-black patients. As with other ACE inhibitors, perindopril may be less effective in lowering blood pressure in black people than in non-blacks, possibly because of a higher prevalence of low-renin states in the black hypertensive population.

Cough:

Cough has been reported with the use of ACE inhibitors. Characteristically, the cough is non-productive, persistent and resolves after discontinuation of therapy. ACE inhibitor-induced cough should be considered as part of the differential diagnosis of cough.

Surgery/Anaesthesia:

In patients undergoing major surgery or during anaesthesia with agents that produce hypotension, Covinace Tablet may block angiotensin II formation secondary to compensatory renin release. The treatment should be discontinued one day prior to the surgery. If hypotension occurs and is considered to be due to this mechanism, it can be corrected by volume expansion.

Hyperkalaemia:

Elevations in serum potassium have been observed in some patients treated with ACE inhibitors, including perindopril. Risk factors for the development of hyperkalaemia include those with renal insufficiency, worsening of renal function, age (> 70 years), diabetes mellitus, intercurrent events, in particular dehydration, acute cardiac decompensation, metabolic acidosis and concomitant use of potassium-sparing diuretics (e.g. spironolactone, eplerenone, triamterene, or amiloride), potassium supplements or potassium-containing salt substitutes; or those patients taking other drugs associated with increases in serum potassium (e.g. heparin, co-trimoxazole also known as trimethoprim/sulfamethoxazole). The use of potassium supplements, potassium-sparing diuretics, or potassium-containing salt substitutes particularly in patients with impaired renal function may lead to a significant increase in serum potassium. Hyperkalaemia can cause serious, sometimes fatal arrhythmias. If concomitant use of the above-mentioned agents is deemed appropriate, they should be used with caution and with frequent monitoring of serum potassium.

Diabetic patients:

In diabetic patients treated with oral antidiabetic agents or insulin, glycaemic control should be closely monitored during the first month of treatment with an ACE inhibitor.

Lithium:

The combination of lithium and perindopril is generally not recommended.

Potassium-sparing diuretics, potassium supplements or potassium-containing salt substitutes:

The combination of perindopril and potassium-sparing diuretics, potassium supplements or potassium-containing salt substitutes is generally not recommended.

Dual blockade of the renin-angiotensin-aldosterone system (RAAS):

There is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren increases the risk of hypotension, hyperkalaemia and decreased renal function (including acute renal failure). Dual blockade of RAAS through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is therefore not recommended.

If dual blockade therapy is considered absolutely necessary, this should only occur under specialist supervision and subject to frequent dose monitoring of renal function, electrolytes and blood pressure. ACE-inhibitors and angiotensin II receptor blockers should not be used concomitantly in patients with diabetic nephropathy.

Primary aldosteronism:

Patients with primary hyperaldosteronism generally will not respond to anti-hypertensive drugs acting through inhibition of the renin-angiotensin system. Therefore, the use of this product is not recommended.

attn	customer	Pharmaniaga Manufacturing Berhad	date	13.04.2020
1 colours	process colour:	Black	Please Chop & Sign For Approval	
size	297 x 210mm			
description	Covinace 8mg Leaflet (Front)			
	FocusPrint SDN BHD	t: 603-8766 6030 f: 603-8766 6033 (Factory)	website: www.focusprint.com.my	
artwork prepared by:	cynthia yap	email: graphic@focusprint.info (graphic Dept)	date:	

IMPORTANT ! Please note that this colour print is for visual purpose only. Output colour might differ in actual production.

ARTWORK LOG		
Revision no.	Date	Reason for Change
01	02.05.19	- Size amend to A3 (420x297mm).
02	15.05.19	- Amend Manufacturer wording.
03	21.06.19	- Remove 'pharmaniaga' logo
04	28.06.19	- Amend wording
05	28.06.19	- Amend wording
06	02.07.19	- Omit line
07	06.08.19	- Amend size to A4.
08	21.08.19	- Amend wording.
09	13.04.2020	- Amend wording.
10	13.04.2020	- Missing t.

Excipients:

Due to the presence of lactose, patients with rare hereditary problems of galactose intolerance, glucose-galactose malabsorption, or the Lapp lactase deficiency should not take this medicinal product.

**PREGNANCY AND LACTATION
INCREASED RISK OF BIRTH DEFECTS, FOETAL AND NEONATAL MORBIDITY AND DEATH WHEN USED THROUGHOUT PREGNANCY.**

The use of ACE inhibitors is not recommended during the first trimester of pregnancy. The use of ACE inhibitors is contra-indicated during the second and third trimester of pregnancy.

Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors during the first trimester of pregnancy has not been conclusive; however, a small increase in risk cannot be excluded. Unless continued ACE inhibitor therapy is considered essential, patients planning pregnancy should be changed to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with ACE inhibitors should be stopped immediately, and, if appropriate, alternative therapy should be started.

Exposure to ACE inhibitor therapy during the second and third trimesters is known to induce human fetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia). Should exposure to ACE inhibitor have occurred from the second trimester of pregnancy, ultrasound check of renal function and skull is recommended. Infants whose mothers have taken ACE inhibitors should be closely observed for hypotension.

Lactation:

Because no information is available regarding the use of Covinace Tablet during breastfeeding, Covinace Tablet is not recommended and alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.

INTERACTIONS WITH OTHER MEDICAMENTS**Dual blockade of the Renin-Angiotensin-System (RAS) with ACE inhibitors, ARBs or aliskiren**

The concomitant use of ACE inhibitors, including perindopril with other agents acting on the RAS is associated with an increased incidence of hypotension, hyperkalaemia, and changes in renal function compared to monotherapy. It is recommended to monitor blood pressure, renal function and electrolytes in patients on perindopril and other agents that affect the RAS. The concomitant use of ACE inhibitors, including perindopril, or of ARBs with aliskiren, should be avoided in patients with severe renal impairment (GFR <30 ml/min). The concomitant use of ACE inhibitors, including perindopril, or of ARBs with aliskiren is contraindicated in patients with Type 2 diabetes.

Medicinal products inducing hyperkalaemia

Some medicinal products or therapeutic classes may increase the occurrence of hyperkalaemia: aliskiren, potassium salts, potassium-sparing diuretics, ACE inhibitors, angiotensin-II receptors antagonists, NSAIDs, heparins, immunosuppressant agents such as ciclosporin or tacrolimus, trimethoprim. The combination of these medicinal products increases the risk of hyperkalaemia.

Estramustine

Risk of increased adverse effects such as angioneurotic oedema (angioedema).

Racecadotril

ACE inhibitors (e.g. perindopril) are known to cause angioedema. This risk may be elevated when used concomitantly with racecadotril (a medicinal product used against acute diarrhoea).

mTOR inhibitors (e.g. sirolimus, everolimus, temsirolimus)

Patients taking concomitant mTOR inhibitors therapy may be at increased risk for angioedema.

Co-trimoxazole (trimethoprim/sulfamethoxazole)

Patients taking concomitant co-trimoxazole (trimethoprim/sulfamethoxazole) may be at increased risk for hyperkalaemia.

Potassium-sparing diuretics (e.g. triamterene, amiloride...), potassium salts

Hyperkalaemia (potentially lethal), especially in conjunction with renal impairment (additive hyperkalaemic effects). The combination of perindopril with the above-mentioned medicinal products is not recommended. If concomitant use is nonetheless indicated, they should be used with caution and with frequent monitoring of serum potassium. For use of spironolactone in heart failure, see below.

Lithium

Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with ACE inhibitors. Concomitant use of thiazide diuretics may increase the risk of lithium toxicity and enhance the already increased risk of lithium toxicity with ACE inhibitors. Use of perindopril with lithium is not recommended, but if the combination proves necessary, careful monitoring of serum lithium levels should be performed.

Concomitant use which requires special care**Antidiabetic agents (insulins, oral hypoglycaemic agents)**

Epidemiological studies have suggested that concomitant administration of ACE inhibitors and antidiabetic medicines (insulins, oral hypoglycaemic agents) may cause an increased blood-glucose lowering effect with risk of hypoglycaemia. This phenomenon appeared to be more likely to occur during the first weeks of combined treatment and in patients with renal impairment.

Badlofen

Increased antihypertensive effect. Monitor blood pressure and adapt antihypertensive dose if necessary.

Non-potassium-sparing diuretics

Patients on diuretics, and especially those who are volume and/or salt depleted, may experience excessive reduction in blood pressure after initiation of therapy with an ACE inhibitor.

The possibility of hypotensive effects can be reduced by discontinuation of the diuretic, by increasing volume or salt intake prior to initiating therapy with low and progressive doses of perindopril.

In arterial hypertension, when prior diuretic therapy can have caused salt/volume depletion, either the diuretic must be discontinued before initiating the ACE inhibitor, in which case a non-potassium-sparing diuretic can be thereafter reintroduced or the ACE inhibitor must be initiated with a low dose and progressively increased. In diuretic-treated congestive heart failure, the ACE inhibitor should be initiated at a very low dose, possibly after reducing the dose of the associated non-potassium-sparing diuretic.

In all cases, renal function (creatinine levels) must be monitored during the first few weeks of ACE inhibitor therapy.

Potassium-sparing diuretics (eplerenone, spironolactone)

With eplerenone or spironolactone at doses between 12.5 mg to 50 mg by day and with low doses of ACE inhibitors:

In the treatment of class II-IV heart failure (NYHA) with an ejection fraction <40%, and previously treated with ACE inhibitors and loop diuretics, risk of hyperkalaemia, potentially lethal, especially in case of non-observance of the prescription recommendations on this combination.

Before initiating the combination, check the absence of hyperkalaemia and renal impairment.

A close monitoring of the kalaemia and creatinaemia is recommended in the first month of the treatment once a week at the beginning and, monthly thereafter.

Non-steroidal anti-inflammatory medicinal products (NSAIDs) including acetylsalicylic acid ≥3 g/day

When ACE-inhibitors are administered simultaneously with non-steroidal anti-inflammatory medicinal products (i.e. acetylsalicylic acid at anti-inflammatory dose regimens, COX-2 inhibitors and non-selective NSAIDs), attenuation of the antihypertensive effect may occur. Concomitant use of ACE-inhibitors and NSAIDs may lead to an increased risk of worsening of renal function, including possible acute renal failure, and an increase in serum potassium, especially in patients with poor pre-existing renal function. The combination should be administered with caution, especially in the elderly. Patients should be adequately hydrated and consideration should be given to monitoring renal function after initiation of concomitant therapy, and periodically thereafter.

Antihypertensive agents and vasodilators

Concomitant use of these agents may increase the hypotensive effects of perindopril. Concomitant use with nitroglycerin and other nitrates, or other vasodilators, may further reduce blood pressure.

Gliptins (linagliptin, saxagliptin, sitagliptin, vildagliptin)

Increased risk of angioedema, due to dipeptidyl peptidase IV (DPP-IV) decreased activity by the gliptin, in patients co-treated with an ACE inhibitor.

Tricyclic antidepressants / Antipsychotics / Anesthetics

Concomitant use of certain anaesthetic medicinal products, tricyclic antidepressants and antipsychotics with ACE inhibitors may result in further reduction of blood pressure.

Sympathomimetics

Sympathomimetics may reduce the antihypertensive effects of ACE inhibitors.

Gold

Nitritoid reactions (symptoms include facial flushing, nausea, vomiting and hypotension) have been reported rarely in patients on therapy with injectable gold (sodium aurothiomalate) and concomitant ACE inhibitor therapy including perindopril.

ADVERSE EFFECTS**Blood and the lymphatic System Disorders**

Eosinophilia, agranulocytosis or pancytopenia, haemoglobin decreased and haematocrit decreased, leucopenia/neutropenia, haemolytic anaemia in patients with a congenital deficiency of G-6PDH and thrombocytopenia.

Metabolism and Nutrition Disorders

Hypoglycaemia, hyperkalaemia (reversible on discontinuation) and hyponatraemia.

Psychiatric Disorders

Mood disturbances and sleep disorder.

Nervous System Disorders

Dizziness, headache, paraesthesia, vertigo, somnolence, syncope and confusion.

Eye Disorders

Visual disturbances.

Ear and labyrinth Disorders

Tinnitus.

Cardiac Disorders

Palpitations, tachycardia, angina pectoris, arrhythmia, myocardial infarction (possibly secondary to excessive hypotension in high risk patients), hypotension (and effects related to hypotension), vasculitis and stroke possibly secondary to excessive hypotension in high-risk patients.

Respiratory, Thoracic and Mediastinal Disorders

Cough, dyspnea, bronchospasm, eosinophilic pneumonia and rhinitis.

Gastro-intestinal Disorders

Abdominal pain, constipation, diarrhoea, dysgeusia, dyspepsia, nausea, vomiting, dry mouth and pancreatitis.

Hepato-biliary Disorders

Hepatitis either cytolytic or cholestatic.

Skin and Subcutaneous Tissue Disorders

Pruritis, rash, urticaria, angioedema (of face, extremities, lips, mucous membranes, tongue, glottis and/or larynx), photosensitivity reactions, pemphigoid, hyperhidrosis, psoriasis worsening and erythema multiforme.

Musculoskeletal and Connective Tissue Disorders

Muscle cramps, arthralgia and myalgia.

Renal and Urinary Disorders

Renal insufficiency and acute renal failure.

Reproductive System and Breast Disorders

Erectile dysfunction.

General Disorders and Administration Site Condition

Asthenia, chest pain, malaise, oedema peripheral and pyrexia.

Investigations

Blood urea increased, blood creatinine increased, blood bilirubin increased and hepatic enzyme increased.

Injury, poisoning and procedural complications

Fall.

EFFECTS ON ABILITY TO DRIVE AND USE MACHINES

Perindopril Tablets has no direct influence on the ability to drive and use machines but individual reactions related to low blood pressure may occur in some patients, particularly at the start of treatment or in combination with another anti-hypertensive medication. As a result, the ability to drive or operate machinery may be impaired.

DOSAGE AND ADMINISTRATION

The dose should be individualized according to the patient profile and blood pressure response.

Hypertension

Perindopril may be used in monotherapy or in combination with other classes of antihypertensive therapy.

The recommended starting dose is 4 mg given once daily in the morning.

Patients with a strongly activated renin-angiotensin-aldosterone system (in particular, renovascular hypertension, salt and/or volume depletion, cardiac decompensation or severe hypertension) may experience an excessive drop in blood pressure following the initial dose.

A starting dose of 2 mg is recommended in such patients and the initiation of treatment should take place under medical supervision.

The dose may be increased to 8 mg once daily after one month of treatment.

Symptomatic hypotension may occur following initiation of therapy with Perindopril; this is more likely in patients who are being treated concurrently with diuretics. Caution is therefore recommended since these patients may be volume and/or salt depleted.

If possible, the diuretic should be discontinued 2 to 3 days before beginning therapy with Perindopril.

In hypertensive patients in whom the diuretic cannot be discontinued, therapy with Perindopril should be initiated with a 2 mg dose. Renal function and serum potassium should be monitored. The subsequent dosage of Covinace Tablet should be adjusted according to blood pressure response. If required, diuretic therapy may be resumed.

In elderly patients, treatment should be initiated at a dose of 2 mg which may be progressively increased to 4 mg after one month then to 8 mg if necessary, depending on renal function (refer Table 1: dosage adjustment in renal impairment)

Stable coronary artery disease

Perindopril should be introduced at a dose of 4 mg once daily for two weeks, then increased to 8 mg once daily, depending on renal function and provided that the 4 mg dose is well tolerated.

Elderly patients should receive 2 mg once daily for one week, then 4 mg once daily the next week, before increasing the dose up to 8 mg once daily depending on renal function (refer Table 1: dosage adjustment in renal impairment). The dose should be increased only if the previous lower dose is well tolerated.

Special populations**Patients with renal impairment**

Dosage in patients with renal impairment should be based on creatinine clearance as outlined in table 1 below:

Table 1: dosage adjustment in renal impairment

Creatinine clearance (ml/min)	Recommended dose
Clcr ≥ 60	4 mg per day
30 < Clcr < 60	2 mg per day
15 < Clcr < 30	2 mg every other day
Haemodialysed patients *	
Clcr < 15	2 mg on the day of dialysis

*Dialysis clearance of perindoprilat is 70 ml/min.

For patients on haemodialysis, the dose should be taken after dialysis.

Patients with hepatic impairment

No dosage adjustment is necessary in patients with hepatic impairment (see sections warnings and precautions and pharmacokinetics)

Paediatric population

The safety and efficacy of perindopril in children and adolescents aged below 18 years have not been established.

Currently available data are described in section pharmacodynamics but no recommendation on a posology can be made.

Therefore, use in children and adolescents is not recommended.

ROUTE OF ADMINISTRATION

Oral

OVERDOSE AND TREATMENT

Limited data are available on overdose in humans. Symptoms associated with overdose of ACE inhibitors may include hypotension, circulatory shock, electrolyte disturbances, renal failure, hyperventilation, tachycardia, palpitations, bradycardia, dizziness, anxiety, and cough.

The recommended treatment of overdose is intravenous infusion of sodium chloride 9 mg/ml (0.9%) solution. If hypotension occurs, the patient should be placed in the shock position. If available, treatment with angiotensin II infusion and/or intravenous catecholamines may also be considered. Perindopril may be removed from the general circulation by haemodialysis. (See Special warnings and precautions for use, Haemodialysis Patients.) Pacemaker therapy is indicated for therapy-resistant bradycardia. Vital signs, serum electrolytes and creatinine concentrations should be monitored continuously.

STORAGE CONDITION

Store below 30°C.

Protect from light

SHELF LIFE

Product should not be used beyond the expiry date imprinted on the product packaging

PRESENTATION

In blisters of 30 tablets.

Date of Revision: 13th April 2020

PRODUCT REGISTRATION HOLDER/MANUFACTURER:

Pharmaniaga Manufacturing Berhad (60016-D)
11A, Jalan P/1, Kawasan Perusahaan Bangi,
43650 Bandar Baru Bangi, Selangor Darul Ehsan, Malaysia

PRP 0562a.2 130420

attn	customer Pharmaniaga Manufacturing Berhad	date 13.04.2020
1 colours	process colour: Black	Please Chop & Sign For Approval
size 297 x 210mm		
description Covinace 8mg Leaflet (Back)		
 FocusPrint SDN BHD	t: 603-8766 6030 f: 603-8766 6033 (Factory) website: www.focusprint.com.my	date:
artwork prepared by: cynthia yap	email: graphic@focusprint.info (graphic Dept)	

IMPORTANT ! Please note that this colour print is for visual purpose only. Output colour might differ in actual production.

ARTWORK LOG

Revision no.	Date	Reason for Change
01	02.05.19	- Size amend to A3 (420x297mm).
02	15.05.19	- Amend Manufacturer wording.
03	21.06.19	- Remove 'pharmaniaga' logo
04	28.06.19	- Amend wording
05	28.06.19	- Amend wording
06	02.07.19	- Omit line
07	06.08.19	- Amend size to A4.
08	21.08.19	- Amend wording.
09	13.04.2020	- Amend wording.
10	13.04.2020	- Missing t.